PortfoliosLab logo
Pharmaron Beijing Co Ltd (3759.HK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

CNE100003PG4

Highlights

Market Cap

HK$41.94B

EPS (TTM)

HK$1.07

PE Ratio

12.46

Total Revenue (TTM)

HK$12.70B

Gross Profit (TTM)

HK$4.37B

Year Range

HK$7.98 - HK$24.85

Target Price

HK$20.09

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of HK$10,000 in Pharmaron Beijing Co Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-40.00%-20.00%0.00%20.00%40.00%60.00%80.00%100.00%December2025FebruaryMarchAprilMay
-22.31%
78.36%
3759.HK (Pharmaron Beijing Co Ltd)
Benchmark (^GSPC)

Returns By Period

Pharmaron Beijing Co Ltd (3759.HK) returned -2.40% year-to-date (YTD) and 43.23% over the past 12 months.


3759.HK

YTD

-2.40%

1M

14.43%

6M

-17.17%

1Y

43.23%

5Y*

-12.53%

10Y*

N/A

^GSPC (Benchmark)

YTD

-3.70%

1M

13.67%

6M

-5.18%

1Y

9.18%

5Y*

14.14%

10Y*

10.43%

*Annualized

Monthly Returns

The table below presents the monthly returns of 3759.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-0.42%9.23%4.16%-15.73%2.22%-2.40%
2024-36.03%3.95%-8.94%1.36%1.24%-11.94%13.85%-7.07%67.79%0.27%-11.30%6.00%-8.44%
20236.00%-23.52%-24.94%2.73%-14.62%-16.26%27.91%-9.63%1.86%0.11%1.29%-16.30%-55.34%
2022-17.91%-4.41%1.11%4.66%-5.26%25.49%-18.59%-18.45%-26.85%-30.80%68.18%21.96%-31.94%
202113.89%-11.13%10.78%9.67%15.39%11.57%-17.83%1.47%7.94%-9.02%-5.19%-25.14%-7.99%
202014.48%6.43%-4.81%22.10%2.11%27.52%5.19%22.40%-6.41%16.08%-15.91%39.21%201.93%
2019-0.71%3.69%2.96%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 76, 3759.HK is among the top 24% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of 3759.HK is 7676
Overall Rank
The Sharpe Ratio Rank of 3759.HK is 7272
Sharpe Ratio Rank
The Sortino Ratio Rank of 3759.HK is 7878
Sortino Ratio Rank
The Omega Ratio Rank of 3759.HK is 7979
Omega Ratio Rank
The Calmar Ratio Rank of 3759.HK is 7777
Calmar Ratio Rank
The Martin Ratio Rank of 3759.HK is 7373
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Pharmaron Beijing Co Ltd (3759.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The current Pharmaron Beijing Co Ltd Sharpe ratio is 0.55. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Pharmaron Beijing Co Ltd with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.00December2025FebruaryMarchAprilMay
0.55
0.45
3759.HK (Pharmaron Beijing Co Ltd)
Benchmark (^GSPC)

Dividends

Dividend History

Pharmaron Beijing Co Ltd provided a 1.59% dividend yield over the last twelve months, with an annual payout of HK$0.22 per share.


0.00%0.50%1.00%1.50%2.00%HK$0.00HK$0.10HK$0.20HK$0.30HK$0.4020202021202220232024
Dividends
Dividend Yield
PeriodTTM20242023202220212020
DividendHK$0.22HK$0.22HK$0.33HK$0.35HK$0.16HK$0.07

Dividend yield

1.59%1.56%2.08%0.98%0.30%0.12%

Monthly Dividends

The table displays the monthly dividend distributions for Pharmaron Beijing Co Ltd. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00
2024HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.22HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.22
2023HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.33HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.33
2022HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.35HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.35
2021HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.16HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.16
2020HK$0.07HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.07

Dividend Yield & Payout


Dividend Yield

Pharmaron Beijing Co Ltd has a dividend yield of 1.59%, which signifies it pays a smaller percentage of its stock price in dividends to its shareholders compared to other companies in the market.

Payout Ratio

Pharmaron Beijing Co Ltd has a payout ratio of 20.46%, which is below the market average. This means Pharmaron Beijing Co Ltd returns a smaller proportion of its earnings to shareholders as dividends, suggesting it retains a higher portion for reinvestment, growth, or debt payment.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-80.00%-60.00%-40.00%-20.00%0.00%December2025FebruaryMarchAprilMay
-84.26%
-7.86%
3759.HK (Pharmaron Beijing Co Ltd)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Pharmaron Beijing Co Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Pharmaron Beijing Co Ltd was 90.78%, occurring on Aug 23, 2024. The portfolio has not yet recovered.

The current Pharmaron Beijing Co Ltd drawdown is 84.26%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-90.78%Jun 29, 2021777Aug 23, 2024
-37.47%Jan 26, 202129Mar 9, 202148May 20, 202177
-28.72%Feb 18, 202025Mar 23, 202020Apr 22, 202045
-23.25%Nov 10, 202015Nov 30, 202015Dec 21, 202030
-14.96%Aug 31, 20209Sep 10, 202020Oct 12, 202029

Volatility

Volatility Chart

The current Pharmaron Beijing Co Ltd volatility is 33.25%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%December2025FebruaryMarchAprilMay
33.25%
11.11%
3759.HK (Pharmaron Beijing Co Ltd)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Pharmaron Beijing Co Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Pharmaron Beijing Co Ltd, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -19.4%.


0.000.200.400.600.8020212022202320242025
0.19
0.23
Actual
Estimate

Valuation

The Valuation section provides an overview of how Pharmaron Beijing Co Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for 3759.HK, comparing it with other companies in the Biotechnology industry. Currently, 3759.HK has a P/E ratio of 12.5. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for 3759.HK relative to other companies in the Biotechnology industry. Currently, 3759.HK has a P/S ratio of 3.2. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for 3759.HK in comparison with other companies in the Biotechnology industry. Currently, 3759.HK has a P/B value of 1.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items